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BACKGROUND
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few 
effective long-term treatments are available. In cardiovascular trials of inhibitors 
of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested 
that such drugs may improve renal outcomes in patients with type 2 diabetes.
METHODS
In this double-blind, randomized trial, we assigned patients with type 2 diabetes 
and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 
inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated 
glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-
surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 
5000) and were treated with renin–angiotensin system blockade. The primary 
outcome was a composite of end-stage kidney disease (dialysis, transplantation, or 
a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the 
serum creatinine level, or death from renal or cardiovascular causes. Prespecified 
secondary outcomes were tested hierarchically.
RESULTS
The trial was stopped early after a planned interim analysis on the recommenda-
tion of the data and safety monitoring committee. At that time, 4401 patients had 
undergone randomization, with a median follow-up of 2.62 years. The relative risk 
of the primary outcome was 30% lower in the canagliflozin group than in the 
placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respec-
tively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). 
The relative risk of the renal-specific composite of end-stage kidney disease, a 
doubling of the creatinine level, or death from renal causes was lower by 34% 
(hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-
stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; 
P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, 
myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) 
and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; 
P<0.001). There were no significant differences in rates of amputation or fracture.
CONCLUSIONS
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and 
cardiovascular events was lower in the canagliflozin group than in the placebo group 
at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; 
CREDENCE ClinicalTrials.gov number, NCT02065791.)
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The increasing prevalence of type 2 diabetes during recent decades1 is the primary factor accounting for the substan-
tial global increase in end-stage kidney disease. 
Currently, more than 3 million people worldwide 
are estimated to be receiving treatment for kid-
ney failure, with predictions that the number will 
increase to more than 5 million by 2035.2 The 
only currently approved treatment for renopro-
tection in patients with type 2 diabetes is renin–
angiotensin system blockade, which was first 
shown to be effective 18 years ago.3,4
Inhibitors of sodium–glucose cotransporter 2 
(SGLT2) were developed to lower blood glucose 
levels in patients with type 2 diabetes. In several 
trials designed to meet regulatory requirements for 
cardiovascular safety, investigators found reduc-
tions in cardiovascular events with SGLT2 inhibi-
tors.5-7 Secondary and exploratory analyses of 
these trials suggested that SGLT2 inhibition might 
improve renal outcomes; however, some uncer-
tainty persisted, since relatively few patients 
reached end-stage kidney disease and the trial 
patients were at low risk for kidney failure.7-9 We 
designed the CREDENCE (Canagliflozin and Re-
nal Events in Diabetes with Established Nephrop-
athy Clinical Evaluation) trial to assess the effects 
of the SGLT2 inhibitor canaglif lozin on renal 
outcomes in patients with type 2 diabetes and 
albuminuric chronic kidney disease.
Me thods
Trial Design and Oversight
Details regarding the design of this randomized, 
double-blind, placebo-controlled, multicenter clini-
cal trial have been published previously.10 The 
protocol (available with the full text of this article 
at NEJM.org) was reviewed by relevant regulatory 
authorities and ethics committees responsible 
for each trial site. The trial was sponsored by 
Janssen Research and Development as a collabo-
ration between the sponsor, an academic-led 
steering committee, and an academic research 
organization, George Clinical, with operational 
implementation by IQVIA, a contract research 
organization. Technical editorial assistance pro-
vided by MedErgy was funded by the sponsor.
Members of the steering committee designed 
the trial, supervised its conduct, and were respon-
sible for reporting the results. Analyses were per-
formed by the sponsor and independently con-
firmed at George Clinical with the use of original 
data. The first and last authors drafted the first 
version of the manuscript, and all the authors 
contributed to revisions. The decision to submit 
the manuscript for publication was made jointly 
by all the authors, who vouch for the complete-
ness and accuracy of the data and for the fidel-
ity of the trial to the protocol.
Patients
Patients were eligible if they were at least 30 years 
of age and had type 2 diabetes, with a glycated 
hemoglobin level of 6.5 to 12.0% (6.5 to 10.5% 
in Germany, according to a country amendment). 
They were also required to have chronic kidney 
disease, defined as an estimated glomerular fil-
tration rate (GFR, as calculated by the Chronic 
Kidney Disease Epidemiology Collaboration for-
mula) of 30 to <90 ml per minute per 1.73 m2 of 
body-surface area and albuminuria (urinary albu-
min-to-creatinine ratio, >300 to 5000, with albu-
min measured in milligrams and creatinine in 
grams), as measured in a central laboratory. There 
was a prespecified plan to include approximately 
60% of patients with an estimated GFR of 30 to 
<60 ml per minute per 1.73 m2.
All the patients were required to be receiving a 
stable dose of an angiotensin-converting–enzyme 
inhibitor or angiotensin-receptor blocker for at 
least 4 weeks before randomization; a stable dose 
was considered to be either the maximum labeled 
dose or a dose not associated with unacceptable 
side effects. Dual-agent treatment with an angio-
tensin-converting–enzyme inhibitor and an angio-
tensin-receptor blocker, a direct renin inhibitor, 
or a mineralocorticoid-receptor antagonist was not 
allowed.
Patients who had suspected nondiabetic kid-
ney disease or type 1 diabetes, had been treated 
with immunosuppression for kidney disease, or 
had a history of dialysis or kidney transplantation 
were excluded. Full inclusion and exclusion crite-
ria are described in the Supplementary Appendix, 
available at NEJM.org. All the patients provided 
written informed consent.
Trial Procedures
The patients were prescreened to determine the 
estimated GFR and urinary albumin-to-creatinine 
ratio by medical-chart review or prospective labo-
ratory assessment. The patients who met the eli-
gibility criteria at screening were included in a 
A Quick Take is 
available at 
NEJM.org 
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2-week, single-blind, placebo run-in period and 
were eligible for randomization if they had re-
ceived at least 80% of single-blind placebo dur-
ing the run-in period.
The patients were randomly assigned in a 
double-blind fashion (1:1) to receive either cana-
gliflozin (100 mg orally once daily) or matching 
placebo with the use of randomly permuted blocks, 
with stratification according to the category of 
estimated GFR (30 to <45 ml, 45 to <60 ml, or 
60 to <90 ml per minute per 1.73 m2) at screen-
ing. The administration of canagliflozin or pla-
cebo was to be continued until trial completion, 
initiation of dialysis, kidney transplantation, 
occurrence of diabetic ketoacidosis, pregnancy, 
or receipt of a disallowed therapy.
After randomization, trial visits were con-
ducted at weeks 3, 13, and 26 and then alternated 
between telephone calls and in-clinic visits at 
13-week intervals. Additional testing of blood at 
either the central or local laboratory and safety 
assessments were permitted at any time at the 
discretion of the investigators. The use of other 
background therapy for glycemic management 
and control of cardiovascular risk factors was rec-
ommended in accordance with local guidelines.
During the trial, an increased risk of lower 
limb amputation was identified in another trial 
of canagliflozin.5 A protocol amendment for the 
present trial in May 2016 asked investigators to 
examine patients’ feet at each trial visit and tem-
porarily interrupt the assigned treatment in pa-
tients with any active condition that might lead 
to amputation.
Outcomes
The primary outcome was a composite of end-
stage kidney disease (dialysis for at least 30 days, 
kidney transplantation, or an estimated GFR of 
<15 ml per minute per 1.73 m2 sustained for at 
least 30 days according to central laboratory as-
sessment), doubling of the serum creatinine level 
from baseline (average of randomization and 
prerandomization value) sustained for at least 30 
days according to central laboratory assessment, 
or death from renal or cardiovascular disease.
Secondary outcomes that were planned for 
sequential hierarchical testing were specified in 
the following order: first, a composite of cardio-
vascular death or hospitalization for heart failure; 
second, a composite of cardiovascular death, 
myocardial infarction, or stroke; third, hospital-
ization for heart failure; fourth, a composite of 
end-stage kidney disease, doubling of the serum 
creatinine level, or renal death; fifth, cardiovas-
cular death; sixth, death from any cause; and 
seventh, a composite of cardiovascular death, 
myocardial infarction, stroke, or hospitalization 
for heart failure or for unstable angina. All other 
efficacy outcomes were exploratory.
Safety evaluations included laboratory testing 
and assessments of adverse events. All renal and 
cardiovascular outcomes that were part of the 
primary and secondary outcomes, as well as key 
safety outcomes (fractures, pancreatitis, keto-
acidosis, and renal-cell carcinoma), were adjudi-
cated by independent adjudication committees 
whose members were unaware of trial-group 
assignments. (Details regarding trial outcomes 
are provided in the Supplementary Appendix.)
Statistical Analysis
The trial was designed to be event-driven, with the 
enrollment of at least 4200 patients (844 events) 
required to provide a power of 90% to detect a 
risk of the primary outcome that was 20% lower 
in the canagliflozin group than in the placebo 
group at an alpha level of 0.045 after adjustment 
for one interim analysis. A single interim analy-
sis was to be conducted by an independent data 
monitoring committee after the primary out-
come had occurred in 405 patients. Prespecified 
stopping guidance that was provided to the data 
monitoring committee by the steering commit-
tee proposed possible recommendation of early 
cessation if clear evidence of benefit was ob-
served for the primary outcome (P<0.01) and the 
composite of end-stage kidney disease or death 
from renal or cardiovascular causes (P<0.025), 
with consideration of the overall balance of risks 
and benefits.
In the intention-to-treat population, we used 
a stratified Cox proportional-hazards model to 
analyze the primary and secondary outcomes, 
according to the category of estimated GFR at 
screening. Data were censored on October 30, 
2018, or the date of last known contact, which 
included the last trial visit (either in-clinic or 
telephone) or the date of alternative contact con-
firming that the patient was alive at the time of 
trial closure.
If the trial was to be stopped at the interim 
analysis, the significance level for the primary 
outcome would be determined by the alpha spend-
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ing function (two-sided level of 0.022 for 585 
events), and the secondary outcomes would be 
tested at a two-sided level of 0.038, to account 
for type I error inflation in the group sequential 
design. Subgroup analyses were assessed by 
tests for the interaction between the trial group 
and the subgroup in stratified Cox proportional-
hazards models without adjustment for multiple 
testing. We used mixed models for repeated mea-
sures to analyze changes in intermediate out-
comes over time in the on-treatment analysis 
population (unless otherwise noted), assuming 
an unstructured covariance and adjusting for the 
baseline value, trial group, category of estimated 
GFR at screening, trial visit, interaction between 
trial group and visit, and interaction between 
baseline value and visit. All available measure-
ments were used with no distinction made for 
missing outcomes for patients who were alive 
and outcomes that were not observed because of 
death. Slope analyses regarding the estimated 
GFR for the acute phase (baseline to week 3), 
chronic phase (week 3 to end of treatment), and 
total slope through week 130 are described in 
the Supplementary Appendix.
We used the data set for all treated patients 
through 30 days after the last dose for the safety 
analyses (on-treatment analysis) and used the on-
study analysis that included all treated patients 
through the end of the trial to evaluate selected 
adverse events, including cancer, amputation, and 
fracture.
We calculated the numbers of patients who 
needed to be treated to prevent one event during 
2.5 years as the reciprocal of the between-group 
difference in cumulative incidence at 2.5 years on 
the basis of the Kaplan–Meier curve. All analyses 
were performed with the use of SAS software, 
version 9.4 (SAS Institute).
R esult s
Patients
From March 2014 through May 2017, a total of 
12,900 patients were screened and 4401 under-
went randomization at 690 sites in 34 countries 
(Fig. S1 in the Supplementary Appendix). The 
baseline characteristics of the patients were simi-
lar in the two groups (Table 1, and Tables S1 and 
S2 in the Supplementary Appendix).10 The mean 
age was 63 years, and 33.9% of the patients were 
women. The mean glycated hemoglobin value 
was 8.3%, the mean estimated GFR was 56.2 ml 
per minute per 1.73 m2, and the median urinary 
albumin-to-creatinine ratio was 927, with albu-
min measured in milligrams and creatinine in 
grams.
The requisite number of primary outcome 
events to trigger the interim analysis were ac-
crued by July 2018. The data monitoring com-
mittee advised the steering committee members 
that the prespecified efficacy criteria for early 
cessation had been achieved and recommended 
that the trial be stopped. The trial leadership 
accepted this recommendation, the patients 
were recalled for final visits, and the trial was 
concluded.
At the trial conclusion at a median follow-up 
of 2.62 years (range, 0.02 to 4.53), 1201 patients 
(27.3%) in the two groups had discontinued ther-
apy (Table S3 and Figs. S1 and S2 in the Supple-
mentary Appendix); the rate of adherence to the 
trial regimen was 84% during follow-up. A total 
of 4361 patients (99.1%) were either alive with 
follow-up at the end of the trial or had died be-
fore the final follow-up visit. Consent was with-
drawn by 16 patients (0.4%), and vital status was 
ascertained for all but 6 patients (4395 [99.9%]).
Effect on the Primary Outcome and Renal 
Components
The event rate of the primary composite out-
come of end-stage kidney disease, doubling of 
the serum creatinine level, or renal or cardiovas-
cular death was significantly lower in the cana-
gliflozin group than in the placebo group (43.2 
and 61.2 per 1000 patient-years, respectively), 
which resulted in a 30% lower relative risk (haz-
ard ratio, 0.70; 95% confidence interval [CI], 
0.59 to 0.82; P = 0.00001) (Table 2 and Fig. 1A). 
The effects were consistent across regions and 
other prespecified subgroups (Fig. 2, and Fig. S3 
in the Supplementary Appendix) and for the com-
ponents of end-stage kidney disease (hazard ra-
tio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002) (Table 2 
and Fig. 1C). The effects were also consistent 
across renal components, including the doubling 
of the serum creatinine level (hazard ratio, 0.60; 
95% CI, 0.48 to 0.76; P<0.001) (Table 2) and the 
exploratory outcome of dialysis, kidney trans-
plantation, or renal death (hazard ratio, 0.72; 
95% CI, 0.54 to 0.97) (Table 2 and Fig. 1D). 
Nearly identical results were shown in sensitivity 
analyses that included imputation of missing 
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data (hazard ratio, 0.69; 95% CI, 0.59 to 0.82) or 
that were adjusted for competing risks (hazard 
ratio, 0.70; 95% CI, 0.59 to 0.82).
Secondary and Exploratory Outcomes
Patients in the canagliflozin group also had a 
lower risk of several secondary outcomes tested 
in a hierarchical fashion (Table 2), including the 
composites of cardiovascular death or hospital-
ization for heart failure (hazard ratio, 0.69; 95% 
CI, 0.57 to 0.83; P<0.001), cardiovascular death, 
myocardial infarction, or stroke (hazard ratio, 
0.80; 95% CI, 0.67 to 0.95; P = 0.01), and hospi-
talization for heart failure (hazard ratio, 0.61; 
95% CI, 0.47 to 0.80; P<0.001). The relative risk 
of the composite of end-stage kidney disease, 
doubling of the serum creatinine level, or renal 
death was lower by 34% in the canaglif lozin 
group (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; 
P<0.001) (Table 2 and Fig. 1B).
There was no significant between-group dif-
ference in the risk of cardiovascular death (haz-
ard ratio, 0.78; 95% CI, 0.61 to 1.00; P = 0.05) 
(Table 2 and Fig. 1E), so the differences in all 
subsequent outcomes in the hierarchical testing 
sequence were not formally tested. The hazard 
ratio for death from any cause was 0.83 (95% CI, 
0.68 to 1.02) (Table 2 and Fig. 1F); for the com-
posite of cardiovascular death, myocardial in-
farction, stroke, or hospitalization for heart 
failure or unstable angina, the hazard ratio was 








Age — yr 62.9±9.2 63.2±9.2 63.0±9.2
Female sex — no. (%) 762 (34.6) 732 (33.3) 1494 (33.9)
Race or ethnic group — no. (%)†
White 1487 (67.5) 1444 (65.7) 2931 (66.6)
Black 112 (5.1) 112 (5.1) 224 (5.1)
Asian 425 (19.3) 452 (20.6) 877 (19.9)
Other 178 (8.1) 191 (8.7) 369 (8.4)
Current smoker — no. (%) 341 (15.5) 298 (13.6) 639 (14.5)
Hypertension — no. (%) 2131 (96.8) 2129 (96.8) 4260 (96.8)
Heart failure — no. (%) 329 (14.9) 323 (14.7) 652 (14.8)
Duration of diabetes — yr 15.5±8.7 16.0±8.6 15.8±8.6
Cardiovascular disease — no. (%) 1113 (50.5) 1107 (50.3) 2220 (50.4)
Amputation — no. (%) 119 (5.4) 115 (5.2) 234 (5.3)
Body-mass index‡ 31.4±6.2 31.3±6.2 31.3±6.2
Blood pressure — mm Hg
Systolic 139.8±15.6 140.2±15.6 140.0±15.6
Diastolic 78.2±9.4 78.4±9.4 78.3±9.4
Glycated hemoglobin — % 8.3±1.3 8.3±1.3 8.3±1.3
Estimated GFR — ml/min/1.73 m2§ 56.3±18.2 56.0±18.3 56.2±18.2






*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile 
range.
†  Race or ethnic group was reported by the patients. The designation “other” includes American Indian or Alaska Native, 
Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The baseline estimated glomerular filtration rate (GFR) was missing for one patient in the canagliflozin group.
¶  The albumin-to-creatinine ratio was calculated with albumin measured in milligrams and creatinine measured in 
grams.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI GENOVA on July 11, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;24 nejm.org June 13, 20192300












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI GENOVA on July 11, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;24 nejm.org June 13, 2019 2301
Canagliflozin and Renal Outcomes in Type 2 Diabetes
Effects on Safety Outcomes
Rates of adverse events and serious adverse events 
were similar overall in the canagliflozin group 
and the placebo group (Table 2, and Tables S4 
and S5 in the Supplementary Appendix). There 
was no significant difference in the risk of lower-
limb amputation, with rates of 12.3 versus 11.2 
per 1000 patient-years in the canagliflozin group 
and the placebo group, respectively (hazard ra-
tio, 1.11; 95% CI, 0.79 to 1.56). Rates of fracture 
were also similar in the two groups (hazard ra-
tio, 0.98; 95% CI, 0.70 to 1.37). Rates of diabetic 
ketoacidosis were low but higher in the cana-
gliflozin group than in the placebo group (2.2 vs. 
0.2 per 1000 patient-years) (Table S6 in the Sup-
plementary Appendix).
Effect on Intermediate Outcomes
For glycated hemoglobin, the least-squares mean 
level at 13 weeks was lower in the canaglif lozin 
group than in the placebo group by 0.31 per-
centage points (95% CI, 0.26 to 0.37), and the 
between-group difference narrowed thereafter, 
with an overall mean difference in the reduc-
tion throughout the trial of 0.25 percentage 
points (95% CI, 0.20 to 0.31) (Fig. S4 in the 
Supplementary Appendix). On average, levels 
were lower in the canaglif lozin group for sys-
tolic blood pressure (by 3.30 mm Hg; 95% CI, 
2.73 to 3.87), diastolic blood pressure (by 0.95 
mm Hg; 95% CI, 0.61 to 1.28), and body weight 
(by 0.80 kg; 95% CI, 0.69 to 0.92). The geomet-
ric mean of the urinary albumin-to-creatinine 
ratio was lower by 31% (95% CI, 26 to 35) on 
average during follow-up in the canaglif lozin 
group (Fig. 3A).
The least-squares mean (±SE) change in the 
estimated GFR slope was less in the canagliflozin 
group than in the placebo group (–3.19±0.15 vs. 
–4.71±0.15 ml per minute per 1.73 m2 per year), 
for a between-group difference of 1.52 ml per 
minute per 1.73 m2 per year (95% CI, 1.11 to 1.93) 
(Fig. 3B). During the first 3 weeks, there was a 
greater reduction in the estimated GFR in the 
canagliflozin group than in the placebo group 
(–3.72±0.25 vs. –0.55±0.25 ml per minute per 
1.73 m2), for a between-group difference of 
–3.17 ml per minute per 1.73 m2 (95% CI, –3.87 
to –2.47). Thereafter, the decline in the esti-
mated GFR was slower in the canaglif lozin 
group than in the placebo group (–1.85±0.13 vs. 
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for a difference of 2.74 ml per minute per 1.73 m2 
per year (95% CI, 2.37 to 3.11).
Projected Estimated Effects
On the basis of our trial data, we estimate that 
among 1000 patients in our trial treated for 2.5 
years, the primary composite outcome of end-
stage kidney disease, doubling of the serum 
creatinine level, or renal or cardiovascular death 
would occur in 47 fewer patients in the cana-
gliflozin group than in the placebo group (num-
ber needed to treat [NNT], 22; 95% CI, 15 to 38), 
including 36 fewer composite renal outcomes of 
end-stage kidney disease, doubling of the serum 
creatinine level, or renal death (NNT, 28; 95% 
CI, 19 to 54) and 24 fewer end-stage kidney-
disease events (NNT, 43; 95% CI, 26 to 121). 
Canaglif lozin treatment would also prevent 22 
Figure 2. Subgroup Analysis, According to Estimated Glomerular Filtration Rate (GFR) at Screening and Albuminuria at Baseline.
Shown are the primary composite outcome and renal-specific composite outcome, according to the patients’ estimated GFR at screen-
ing and urinary albumin-to-creatinine ratio (UACR) at baseline, in the canagliflozin group and the placebo group. The albumin-to-creati-
nine ratio was calculated with albumin measured in milligrams and creatinine measured in grams. CV denotes cardiovascular, and ESKD 
end-stage kidney disease.
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Figure 1 (facing page). Primary Composite, Renal,  
and Mortality Outcomes.
Panel A shows the primary composite outcome of 
 end-stage kidney disease, doubling of the serum cre-
atinine level, or renal or cardiovascular death in the 
canagliflozin group and the placebo group. Panel B 
shows the renal-specific composite outcome of end-
stage kidney disease, doubling of serum creatinine 
 level, or renal death. Panel C shows end-stage kidney 
disease, which was defined as the initiation of dialysis 
for at least 30 days, kidney transplantation, or an esti-
mated glomerular filtration rate of less than 15 ml per 
minute per 1.73 m2 of body-surface area that was sus-
tained for at least 30 days, according to central labo-
ratory assessment. Panel D shows the initiation of 
 dialysis, kidney transplantation, or renal death, which 
was an exploratory outcome. Panel E shows death 
from cardiovascular causes, and Panel F death from 
any cause. The insets show the same data on an ex-
panded y axis.
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hospitalizations for heart failure (NNT, 46; 95% 
CI, 29 to 124) and 25 composite events of cardio-
vascular death, myocardial infarction, or stroke 
(NNT, 40; 95% CI, 23 to 165).
Discussion
In this trial, we found that patients with type 2 
diabetes and chronic kidney disease who re-
ceived canagliflozin had a lower risk of the pri-
mary composite outcome of end-stage kidney 
disease, doubling of the serum creatinine level, 
or death from renal or cardiovascular causes 
than those who received placebo. Patients in the 
canagliflozin group also had a lower risk of end-
stage kidney disease, hospitalization for heart 
failure, and the composite of cardiovascular 
death, myocardial infarction, or stroke. These 
results indicate that canagliflozin may be an ef-
fective treatment option for renal and cardiovas-
cular protection in patients with type 2 diabetes 
with chronic kidney disease.
The observed benefits were obtained on a 
background of renin–angiotensin system block-
ade, the only approved renoprotective medica-
tions in type 2 diabetes, a factor that highlights 
the clinical significance of the findings. In con-
trast to completed cardiovascular outcome trials 
of SGLT2 inhibitors,5-7 our trial included a popu-
lation at high risk for kidney failure and had a 
primary outcome of major renal end points. In 
addition, we found that patients who received 
canaglif lozin (including those who had a re-
duced estimated GFR at baseline) had a lower 
risk of the primary outcome overall than those 
in the placebo group, as well as less end-stage 
kidney disease. These findings were observed 
despite very modest between-group differences 
in blood glucose level, weight, and blood pres-
sure and in contrast to previous concern about 
the initial acute reduction in the estimated GFR 
observed with SGLT2 inhibitors. This suggests 
that the mechanism of benefit is likely to be 
independent of glucose levels and may possibly 
stem from a reduction in intraglomerular pres-
sure,11-13 with other possible mechanisms present-
ly being studied.14-17
Our trial population was also at high risk for 
cardiovascular outcomes, with cardiovascular 
death, myocardial infarction, stroke, or hospital-
ization for heart failure occurring in 13.8% of 
the population over a median of 2.62 years of 
follow-up. The significantly lower rates of car-
diovascular outcomes, including the composite 
of cardiovascular death, myocardial infarction, 
or stroke, in the canagliflozin group in our trial 
are consistent with those observed with cana-
gliflozin in the CANVAS (Canagliflozin Cardio-
vascular Assessment Study) Program,5 despite 
the smaller differences in glycemic control. The 
EMPA-REG OUTCOME trial also showed that 
empagliflozin was superior to placebo,6 and the 
DECLARE–TIMI 58 (Dapagliflozin Effect on Car-
Figure 3. Effects on Albuminuria and Estimated GFR.
Panel A shows the effects of canagliflozin and placebo on the urinary albu-
min-to-creatinine ratio in the intention-to-treat population. Panel B shows 
the change from the screening level in the estimated GFR in the on-treat-
ment population. The I bars indicate the 95% confidence interval in Panel 
A and the standard error in Panel B. The albumin-to-creatinine ratio was 
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diovascular Events–Thrombolysis in Myocardial 
Infarction 58) trial showed that dapagliflozin 
was noninferior to placebo for this composite 
outcome.7 The reduction in hospitalization for 
heart failure seen in our trial is consistent with 
results of other trials of SGLT2 inhibitors.5-7,18,19
The similar rates of amputation and fracture 
that we observed with canagliflozin and placebo 
are reassuring and consistent with trials of other 
SGLT2 inhibitors6,7,20 but differ from the CANVAS 
Program findings.5 Whether the increased risk 
of lower limb amputation in the CANVAS Pro-
gram was due to differing trial populations or 
protocols or to chance remains unclear. The 
overall safety profile in our trial is otherwise 
consistent with the known adverse effects asso-
ciated with canagliflozin.
This trial has certain limitations. First, the 
trial was stopped early at a planned interim 
analysis, which may have limited the power for 
some secondary outcomes and may increase the 
risk of overestimating effect sizes.21 However, the 
precision of the effect and the consistency with 
the findings of previous large trials of SGLT2 
inhibitors suggest that this limitation is unlikely 
to have a major effect on our findings. Second, 
we did not measure off-treatment estimated GFR 
levels among the patients who had completed the 
trial, so the differences in the estimated GFR 
values at the end of the trial are probably under-
estimations. Third, we excluded patients who had 
very advanced kidney disease (estimated GFR, 
<30 ml per minute per 1.73 m2), nonalbuminuric 
or microalbuminuric disease, and kidney diseases 
believed to be due to conditions other than type 2 
diabetes, so it is not known whether the findings 
can be generalized to such populations.
In conclusion, among patients with type 2 
diabetes and kidney disease, those in the cana-
gliflozin group had a lower risk of kidney failure 
and cardiovascular events than those in the pla-
cebo group at a median follow-up of 2.62 years.
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Inclusion and Exclusion Criteria 
Inclusion Criteria at Screening Visit 
1. Man or woman ≥30 years-old with a clinical diagnosis of type 2 diabetes mellitus (T2DM). 
2. Glycated hemoglobin (HbA1c) ≥6.5% to ≤12.0%, (≥6.5% to ≤10.5% in Germany). 
3. Estimated glomerular filtration rate (eGFR) ≥30 to <90 mL/min/1.73 m2 (as determined using the 
Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation). 
Note: An overall global target ratio for randomized cohort of approximately 60%:40% for CKD 
Stage 3 (i.e., eGFR ≥30 to <60 mL/min/1.73 m2; first category):CKD Stage 2 (i.e., eGFR ≥60 to <90 
mL/min/1.73 m2; second category) will be monitored centrally. In an effort to limit exposure to 
investigational product and to ensure sufficient experiences in subjects with Stage 3 CKD, entry 
of subjects with Stage 2 CKD (i.e., eGFR ≥60 to <90 mL/min/1.73 m2) may be restricted on a 
regional and/or site basis should the ratio drift substantially off target over the course of the 
recruitment period. 
4.  Urinary albumin:creatinine ratio (UACR) >300 mg/g to ≤5000 mg/g (>33.9 mg/mmol to 
≤565.6 mg/mmol). 
5. All subjects must be on a stable maximum tolerated labeled daily dose of ACEi or ARB for at 
least 4 weeks prior to randomization.  
Note: A maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB) is defined as the maximum approved labeled dose 
for diabetic nephropathy (for agents with an approved indication for diabetic nephropathy in 
patients with T2DM, i.e., losartan and irbesartan) or the maximum approved dose for 
hypertension (for agents without an approved indication for diabetic nephropathy), unless side 




on a maximum labeled daily dose of an ACEi or ARB, investigators will be required to document 
why a higher dose should not be used. 
6.  Women must be: 
 postmenopausal, defined as 
o >45 years of age with amenorrhea for at least 18 months, or 
o >45 years of age with amenorrhea for at least 6 months and <18 months and a 
serum follicle stimulating hormone (FSH) level >40 IU/L, or 
 surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal occlusion 
[which includes tubal ligation procedures as consistent with local regulations]), or otherwise 
be incapable of pregnancy, or 
 heterosexually active and practicing a highly effective method of birth control, including 
hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, 
intrauterine device, double-barrier method (e.g., condoms, diaphragm, or cervical cap with 
spermicidal foam, cream, or gel), or male partner sterilization, and consistent with local 
regulations regarding use of birth control methods for subjects participating in clinical 
studies, for the duration of their participation in the study, or  
 not heterosexually active. 
Note: Subjects who are not heterosexually active at screening must agree to utilize a highly 
effective method of birth control if they become heterosexually active during their participation 
in the study. 
7.  Women of childbearing potential (i.e., those subjects who do not meet the postmenopausal 
definition above), regardless of age, must have a negative urine pregnancy test at baseline (Day 




Note: A serum pregnancy test is acceptable in lieu of a urine pregnancy test if required by local 
regulations. 
8. Willing and able to adhere to the prohibitions and restrictions specified in this protocol. 
9. Subjects must have signed an informed consent document indicating that they understand the 
purpose of and procedures required for the study and are willing to participate in the study. 
Each subject must also sign a separate informed consent form if he or she agrees to provide an 
optional DNA sample for research (where local regulations permit). Refusal to give consent for 
the optional DNA research sample does not exclude a subject from participation in the study. 
Inclusion Criterion for Randomization 
10. Subjects must have ≥80% compliance (by pill count) with single-blind placebo. 
 
Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
Diabetes-related/Metabolic 
1. History of diabetic ketoacidosis or type 1 diabetes mellitus (T1DM). 
2. History of hereditary glucose-galactose malabsorption or primary renal glucosuria. 
Renal/Cardiovascular 
3. Known medical history or clinical evidence suggesting nondiabetic renal disease. 
4. Renal disease that required treatment with immunosuppressive therapy or a history of chronic dialysis 
or renal transplant. 




5. Uncontrolled hypertension (systolic blood pressure [BP] ≥180 and/or diastolic BP ≥100 mmHg) by Week 
–2. 
Note: Subjects not fulfilling BP criteria at the initial screening visit may have their BP-lowering medication 
regimen adjusted, followed by re-evaluation up to the Week –2 run-in period (the ACEi or ARB regimen 
must be stable for at least 4 weeks before Day 1 to be eligible). 
6. Blood potassium level >5.5 mmol/L during screening. 
Note: Subjects in whom hyperkalemia was associated with the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs), β-blockers, or mineralocorticoid receptor antagonists (MRAs; e.g., spironolactone or 
eplerenone), who have been withdrawn from these drugs, and in whom usage of these drugs is not 
indicated in the view of the treating physician, may be included in the study. 
7. Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), 
or cerebrovascular accident within 12 weeks before randomization, or a revascularization procedure is 
planned during the trial. 
8. Current or history of heart failure of New York Heart Association (NYHA) class IV cardiac disease (The 
Criteria Committee of the NYHA).  
9. Electrocardiogram (ECG) findings within 12 weeks before randomization that would require urgent 
diagnostic evaluation or intervention (e.g., new clinically important arrhythmia or conduction 
disturbance). 
Gastrointestinal 





11. Alanine aminotransferase (ALT) levels >2.0 times the upper limit of normal (ULN) or total bilirubin >1.5 
times the ULN, unless in the opinion of the investigator and as agreed upon by the sponsor’s medical 
officer, the findings are consistent with Gilbert’s disease. 
Other Conditions 
12. History of malignancy within 5 years before screening (exceptions: squamous and basal cell 
carcinomas of the skin and carcinoma of the cervix in situ, or a malignancy that in the opinion of the 
investigator, with concurrence with the sponsor’s medical monitor, is considered cured with minimal risk 
of recurrence). 
13. History of human immunodeficiency virus (HIV) antibody positive. 
14. Major surgery within 12 weeks before randomization, or has not fully recovered from surgery. 
15. Any condition that in the opinion of the investigator or sponsor’s medical monitor would make 
participation not in the best interest of the subject, or could prevent, limit, or confound the protocol-
specified assessments. 
16. History of atraumatic amputation within past 12 months of screening, or an active skin ulcer, 
osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening (added 
May 5, 2016). 
Medications/Therapies 
17. Combination use of an ACEi and ARB. 




Note: If deemed clinically appropriate at the discretion of the investigator, subjects may be removed from 
therapy with an MRA or DRI during screening. Subjects who are off therapy with an MRA or DRI for at 
least 8 weeks prior to randomization may be considered eligible for enrollment. 
19. Current use of a sodium glucose co-transporter 2 (SGLT2) inhibitor (within 12 weeks prior to 
randomization). 
20. Current participation in another canagliflozin study or previously exposed to canagliflozin in a prior 
canagliflozin study. 
21. Known allergies, hypersensitivity, or intolerance to canagliflozin or its excipients. 
22. Received an active investigational drug (including vaccines) other than a placebo agent, or used an 
investigational medical device within 12 weeks before Day 1/baseline. 
General 
23. Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study. 
24. Employees of the investigator or study center, with direct involvement in the proposed study or other 
studies under the direction of that investigator or study center, as well as family members of the 
employees or the investigator. 
Note: Investigators should ensure that all study enrollment criteria have been met and determine that 
the subject has not had any interval change in clinical status since the time of the initial screening visit. 
Before randomization, subjects whose clinical status changes after screening such that they now meet an 





Safety Analyses  
Adverse events (AEs) All AEs will be collected and coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) from randomization until 30 days after the last date of blinded 
study medication  
AEs of interest  All malignancies, renal cell carcinoma, fatal pancreatitis, hemorrhagic/necrotizing 
pancreatitis, severe hypersensitivity reactions (e.g., angioedema, anaphylaxis, 
Stevens-Johnson syndrome), photosensitivity reactions, serious AEs of hepatic injury, 
nephrotoxicity/acute kidney injury, venous thromboembolic events, fractures, 
diabetic ketoacidosis (and related AEs including ketoacidosis, metabolic acidosis, or 
acidosis), amputation, and pregnancy  
Hypoglycemia  All episodes of hypoglycemia (both symptomatic and asymptomatic) are recorded on 
a dedicated hypoglycemia electronic case report form (eCRF) 
Safety laboratory tests  Chemistry, hematology, urinalysis  






Primary Endpoint Criteria 
End-stage Kidney Disease (ESKD) 
In the absence of universally accepted guidelines that define the onset of ESKD, the following definitions 
have been developed to identify and adjudicate ESKD events: 
1. Diagnosis 
Worsening uremia in patients progressing from chronic kidney disease (CKD) to ESKD causes characteristic 
symptoms which require renal replacement therapy (RRT) in the form of dialysis or transplantation. The 
requirement of ongoing RRT establishes the diagnosis of ESKD. In some cases, the diagnosis can be made 
in the absence of RRT when certain criteria are fulfilled: 
 Kidney Transplantation: Definitive RRT prescribed when uremic symptoms have already 
occurred, or are anticipated to occur, due to the progression of irreversible CKD. Death during 
the transplant surgery will be considered kidney transplantation. 
 Chronic Dialysis: ESKD will be diagnosed if dialysis is performed for ≥30 days and is not 
subsequently known to recover. Indications for dialysis are indicated in Section 2 below. 
 Dialysis Not Administered: In cases where dialysis is not available or not administered due to 
futility or subject refusal, the diagnosis of ESKD will require a sustained estimated glomerular 
filtration rate (eGFR) of <15 mL/min/1.73 m2 (by CKD Epidemiology Collaboration [CKD-EPI] 
formula and confirmed by repeat central laboratory measure at 30 days or more of the initial 
onset). 
 
2. Onset of ESKD 




 Chronic progression. 
 Acute deterioration, diagnosed when the decline in kidney function is sudden and acute kidney 
injury is superimposed on CKD, resulting in RRT. 
 
3. Confirmation of ESKD 
 In cases where RRT is given in the form of dialysis, the patient will be contacted at 90 days after 
the initiation of dialysis to document if dialysis is continuing. 
 If the patient recovers renal function (defined as patient taken off dialysis because the physician 
evaluates that patient has enough renal function to live independently), the diagnosis of ESKD 
will be rescinded. 
 If the patient is known to have received dialysis for >30 days but <90 days, and not known to 
recover, ESKD will be confirmed. The reason for the unavailability of information beyond 30 days 
should be clearly documented by the investigator. 
 If dialysis was initiated, but not continued for 30 days due to death, futility of therapy, or 
transplantation, the patient will be considered to have reached ESKD. In this situation, the 
reason for discontinuation of dialysis should be clearly documented by the investigator. 
 
4. Date of ESKD 
 If an event is adjudicated as ESKD due to kidney transplantation, the date of the transplantation 
will be the date of the event if transplantation was the first form of RRT given. 
 If an event is adjudicated as ESKD due to initiation of dialysis, the date when dialysis was 




 In cases where dialysis is unavailable, or not administered, the date of ESKD will be when eGFR 
falls below 15 mL/min/1.73 m2. If a confirmatory central laboratory value cannot be collected 
due to death, and there is no evidence of acute kidney injury, the date of the event will be the 
date in which eGFR falls below 15 mL/min/1.73 m2. If local and central laboratory tests are 
collected on the same day, the central laboratory value overrules the local laboratory value. 
Information around the presence or absence of symptoms of uremia will also be collected for all 
patients meeting the ESKD endpoint; however, this will not affect the final adjudication decision, 
which will be based on the primary definition of ESKD as described in Sections 1 to 4 above. 
 Symptomatic Uremia: Symptomatic uremia is diagnosed in the presence of the uremic 
syndrome, which is a constellation of signs and symptom involving several different systems, 
including:  
o General: Pruritus, dry skin, fatigue, anhedonia; 
o Metabolic: Deterioration in nutritional status, recent significant weight loss, electrolyte 
or acid-base disturbances (severe hyperkalemia or severe acidosis); 
o Gastrointestinal: Nausea, vomiting; 
o Neurological: Neuropathy, encephalopathy, psychiatric disturbances, seizures; 
o Volume overload, including difficult-to-control or accelerated hypertension; 
o Bleeding diathesis not attributable to other causes; 
o Pleuritis or pericarditis of uremic origin or other; 
o Severe hyperparathyroidism. 
 Advanced Asymptomatic Uremia: The initiation of dialysis is generally performed when eGFR 
declines to <15 mL/min/1.73 m2 on a subjective basis in anticipation of development of uremic 
symptoms. If no symptoms are documented for initiation of dialysis, asymptomatic uremia will 




values (such as <8 mL/min/1.73 m2), however are initiated RRT in the view of benefits of 
therapy, the diagnosis will be of advanced asymptomatic uremia. 
 
Doubling of Serum Creatinine 
Doubling of serum creatinine will be defined as a ≥2-fold increase in serum creatinine from the baseline 
assessment that persists for ≥30 days and is not thought to be due to reversible cause.  
 
The baseline serum creatinine, as determined by averaging the 2 values closest to randomization, will be 
used to compare subsequent values and determine if doubling of serum creatinine has occurred. 
 
Both central serum creatinine values and local laboratory values may be used to calculate the increase in 
serum creatinine. The investigator will make all reasonable attempts to exclude reversible causes of 
elevation of serum creatinine such as volume depletion or nephrotoxic medication. The event will be 
adjudicated positively once the initial doubling of serum creatinine via local or central laboratory results 
has been confirmed by the central laboratory at ≥30 days, and if the process is determined to be 
irreversible. 
 
If a confirmatory central laboratory value cannot be collected due to death or dialyses and there is no 
evidence of acute kidney injury, the event will be adjudicated positively. 
 
The date of the event will be the date on which the creatinine first doubled. If central and local laboratory 






All deaths will be reviewed by the adjudicators to determine the cause of death, which will be classified 
as either renal death, cardiovascular (CV) death, or non-CV death. 
 
Renal Death 
Renal death refers to deaths in patients who have reached ESKD who die prior to initiating RRT and no 
other cause of death is adjudicated. This may occur in the situations where either the patient refuses RRT 
or both the physician and the patient consider RRT futile and believe that the patients' current quality of 
life, with their expected lifespan, outweighs the quality and quantity of life following RRT. This may also 
occur in situations where dialysis is not available. These events are classified as renal death when death 
occurs following refusal of dialysis AND no other cause of death is adjudicated. When a more specific 
cause of death is adjudicated, such as sepsis or trauma, the more specific cause will be designated as the 
primary cause of death. 
 
CV Death 
CV death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, death 
due to heart failure (HF), death due to stroke, death due to CV procedures, death due to CV hemorrhage, 
and death due to other CV causes. 
1. Death due to acute MI refers to a death by any CV mechanism (e.g., arrhythmia, sudden death, 
HF, stroke, pulmonary embolus, peripheral arterial disease) ≤30 days after an MI related to the 




that there may be assessable mechanisms of CV death during this time period, but for simplicity, 
if the CV death occurs ≤30 days of the MI, it will be considered a death due to MI.  
 
Acute MI should be verified to the extent possible by the diagnostic criteria outlined for acute MI 
or by autopsy findings showing recent MI or recent coronary thrombosis. Death resulting from a 
procedure to treat an MI (percutaneous coronary intervention [PCI], coronary artery bypass graft 
surgery [CABG]), or to treat a complication resulting from MI, should also be considered death 
due to acute MI.  
 
Death resulting from an elective coronary procedure to treat myocardial ischemia (i.e., chronic 
stable angina) or death due to an MI that occurs as a direct consequence of a CV 
investigation/procedure/operation should be considered as a death due to a CV procedure. 
 
2.  Sudden cardiac death refers to a death that occurs unexpectedly, not following an acute MI, and 
includes the following deaths: 
 Death witnessed and occurring without new or worsening symptoms; 
 Death witnessed within 60 minutes of the onset of new or worsening cardiac symptoms, 
unless the symptoms suggest acute MI; 
 Death witnessed and attributed to an identified arrhythmia (e.g., captured on an 
electrocardiographic (ECG) recording, witnessed on a monitor, or unwitnessed but found on 
implantable cardioverter-defibrillator review); 
 Death after unsuccessful resuscitation from cardiac arrest; 
 Death after successful resuscitation from cardiac arrest and without identification of a 




 Unwitnessed death in a subject seen alive and clinically stable ≤24 hours prior to being 
found dead without any evidence supporting a specific non-CV cause of death (information 
regarding the patient’s clinical status preceding death should be provided, if available) 
 
General Considerations 
Unless additional information suggests an alternate specific cause of death (e.g., death due to 
other CV causes), if a patient is seen alive ≤24 hours of being found dead, sudden cardiac death 
should be recorded. For patients who were not observed alive within 24 hours of death, 
undetermined cause of death should be recorded (e.g., a subject found dead in bed, but who had 
not been seen by family for several days). 
3.  Death due to HF refers to a death in association with clinically worsening symptoms and/or signs 
of HF regardless of HF etiology. Deaths due to HF can have various etiologies, including single or 
recurrent MI, ischemic or nonischemic cardiomyopathy, hypertension, or valvular disease. 
4.  Death due to stroke refers to death after a stroke that is either a direct consequence of the stroke 
or a complication of the stroke. Acute stroke should be verified to the extent possible by the 
diagnostic criteria outlined for stroke. 
5.  Death due to CV procedures refers to death caused by the immediate complications of a cardiac 
procedure. 
6.  Death due to CV hemorrhage refers to death related to hemorrhage such as a nonstroke 
intracranial hemorrhage, nonprocedural or nontraumatic vascular rupture (e.g., aortic aneurysm), 
or hemorrhage causing cardiac tamponade. 
7.  Death due to other CV causes refers to a CV death not included in the above categories but with 




Definition of Non-CV Death 
Non-CV death is defined as any death that is not thought to be due to a CV cause. The following is a 





 Infection (includes sepsis); 
 Noninfectious (e.g., systemic inflammatory response syndrome [SIRS]); 
 Hemorrhage that is neither CV bleeding nor a stroke; 
 Non-CV procedure or surgery; 
 Trauma; 
 Suicide; 
 Nonprescription drug reaction or overdose; 
 Prescription drug reaction or overdose; 
 Neurological (non-CV); 
 Malignancy; or 
 Other non-CV, specify: 
 
Definition of Undetermined Cause of Death 
Undetermined cause of death refers to a death not attributable to one of the above categories of CV death 
or to a non-CV cause. Inability to classify the cause of death may be due to lack of information (e.g., the 




to assign the cause of death. This category of death should be avoided as much as possible and should 





Estimated Glomerular Filtration Rate (eGFR) Slope Analyses 
The on-treatment eGFR slope for the acute and chronic phase was analyzed using a two-slope model 
with a knot at week 3, including the fixed effects of treatment, baseline eGFR, screening eGFR strata, 
continuous time, time spline (one knot at Week 3), with two-way interactions of treatment by time, 
treatment by time spline, eGFR strata by time, eGFR strata by time spline, and the random effects of 
intercept, time and time spline. Total slope at week 130 was calculated as a linear contrast of the acute 




Figure S1. Study flow diagram. 
 
*Includes failed prescreening of estimated glomerular filtration rate and/or proteinuria/albuminuria. 
†All randomized participants were in the intent-to-treat population; participants who did not receive 
study drug were excluded from the on-treatment and on-study analysis sets. 
‡Defined as having been followed until a time point between the announcement of the end of study and 












Figure S3. Subgroup analysis of the primary composite endpoint.* 
 





*Subgroup analysis was conducted when the total number of events was greater than 10 for both 
treatment groups (canagliflozin group and placebo) and there was at least 1 event in both groups.  
P values are based on the test of subgroup by treatment interaction in a stratified Cox proportional hazard 





Figure S4. Effects on intermediate outcomes (ITT).* 
A) Glycated hemoglobin 
 





C) Diastolic blood pressure 
 
D) Body weight 
 
 
ITT, intention-to-treat; LS, least square; SE, standard error. 






Table S1. Detailed Baseline Demographic and Disease Characteristics by Randomized Groups* 
Characteristic 
Canagliflozin 
(n = 2202) 
Placebo 
(n = 2199) 
Total 
(N = 4401) 
Age—yr 62.9 ± 9.2 63.2 ± 9.2 63.0 ± 9.2 
Female sex—no. (%) 762 (34.6) 732 (33.3) 1494 (33.9) 
Race—no. (%)     
White 1487 (67.5) 1444 (65.7) 2931 (66.6) 
Black or African American 112 (5.1) 112 (5.1) 224 (5.1) 
Asian 425 (19.3) 452 (20.6) 877 (19.9) 
Other† 178 (8.1) 191 (8.7) 369 (8.4) 
Region—no. (%)     
 North America 574 (26.1) 608 (27.6) 1182 (26.9) 
 Central/South America 476 (21.6) 465 (21.1) 941 (21.4) 
 Europe 454 (20.6) 410 (18.6) 864 (19.6) 
 Rest of the world 698 (31.7) 716 (32.6) 1414 (32.1) 
Current smoker—no. (%)  341 (15.5) 298 (13.6) 639 (14.5) 
History of hypertension—no. (%)  2131 (96.8) 2129 (96.8) 4260 (96.8) 
History of heart failure—no. (%) 329 (14.9) 323 (14.7) 652 (14.8) 
Duration of diabetes—yr 15.5 ± 8.7 16.0 ± 8.6 15.8 ± 8.6 
Drug therapy—no. (%)    
Insulin 1452 (65.9) 1432 (65.1) 2884 (65.5) 
Sulfonylurea  612 (27.8) 656 (29.8) 1268 (28.8) 
Biguanides  1276 (57.9) 1269 (57.7) 2545 (57.8) 




DPP-4 inhibitor 378 (17.2) 373 (17.0) 751 (17.1) 
Statin  1538 (69.8) 1498 (68.1) 3036 (69.0) 
Antithrombotic‡ 1341 (60.9) 1283 (58.3) 2624 (59.6) 
RAAS inhibitor 2201 (>99.9) 2194 (99.8) 4395 (99.9) 
Beta blocker 883 (40.1) 887 (40.3) 1770 (40.2) 
Diuretic 1026 (46.6) 1031 (46.9) 2057 (46.7) 
Microvascular disease history—no. (%)     
Retinopathy  935 (42.5) 947 (43.1) 1882 (42.8) 
Nephropathy  2202 (100) 2199 (100) 4401 (100) 
Neuropathy  1077 (48.9) 1070 (48.7) 2147 (48.8) 
Atherosclerotic vascular disease history—no. (%)||    
Coronary  653 (29.7) 660 (30.0) 1313 (29.8) 
Cerebrovascular  342 (15.5) 358 (16.3) 700 (15.9) 
Peripheral  531 (24.1) 515 (23.4) 1046 (23.8) 
Cardiovascular disease history—no. (%) 1113 (50.5) 1107 (50.3) 2220 (50.4) 
History of amputation—no. (%) 119 (5.4) 115 (5.2) 234 (5.3) 
Body mass index—kg/m2 31.4 ± 6.2 31.3 ± 6.2 31.3 ± 6.2 
Systolic blood pressure—mmHg 139.8 ± 15.6 140.2 ± 15.6 140.0 ± 15.6 
Diastolic blood pressure—mmHg 78.2 ± 9.4 78.4 ± 9.4 78.3 ± 9.4 
Glycated hemoglobin—% 8.3 ± 1.3 8.3 ± 1.3 8.3 ± 1.3 
Cholesterol—mg/dL (mmol/L)    
Total  180.9 ± 51.3 
(4.7 ± 1.3) 
179.8 ± 49.7 
(4.6 ± 1.3) 
180.4 ± 50.5 
 (4.7 ± 1.3) 




(2.2 ± 1.6) (2.2 ± 1.7) (2.2 ± 1.6) 
HDL cholesterol 44.5 ± 13.8  
 (1.2 ± 0.4) 
44.5 ± 13.1  
 (1.2 ± 0.3) 
44.5 ± 13.4 
 (1.2 ± 0.3) 
LDL cholesterol 97.0 ± 42.7 
(2.5 ± 1.1) 
95.9 ± 39.9 
(2.5 ± 1.0) 
96.4 ± 41.3 
(2.5 ± 1.1) 
Ratio of LDL to HDL 2.3 ± 1.1 2.3 ± 1.0 2.3 ± 1.1 
eGFR—mL/min/1.73 m²¶ 56.3 ± 18.2 56.0 ± 18.3 56.2 ± 18.2 
eGFR ≥90 mL/min/1.73 m2—no. (%) 105 (4.8) 106 (4.8) 211 (4.8) 
eGFR ≥60 to <90 mL/min/1.73 m2—no. (%) 788 (35.8) 770 (35.0) 1558 (35.4) 
eGFR ≥45 to <60 mL/min/1.73 m2—no. (%) 630 (28.6) 636 (28.9) 1266 (28.8) 
eGFR ≥30 to <45 mL/min/1.73 m2—no. (%) 594 (27.0) 597 (27.1) 1191 (27.1) 
eGFR ≥15 to <30 mL/min/1.73 m2—no. (%) 83 (3.8) 89 (4.0) 172 (3.9) 
eGFR <15 mL/min/1.73 m2—no. (%) 1 (<0.1) 1 (<0.1) 2 (<0.1) 






Normoalbuminuria—no. (%)# 16 (0.7) 15 (0.7) 31 (0.7) 
Microalbuminuria—no. (%)# 251 (11.4) 245 (11.1) 496 (11.3) 
Nephrotic range macroalbuminuria—no. (%)** 233 (10.6) 270 (12.3) 503 (11.4) 
Non-nephrotic range macroalbuminuria—no. (%)†† 1702 (77.3) 1669 (75.9) 3371 (76.6) 
SD, standard deviation; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4; RAAS, renin 
angiotensin aldosterone system; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, 
estimated glomerular filtration rate; IQR, interquartile range.  




†Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, 
unknown, and not reported.  
‡Includes anticoagulation and antiplatelet agents, including aspirin. 
||Some participants had ≥1 type of atherosclerotic disease.  
¶Values for baseline eGFR categories calculated based on N of 2201 for canagliflozin, 2199 for placebo, 
and 4400 for the total population.  
#Eligibility was based on screening urine albumin:creatinine ratio >300 mg/g to ≤5000 mg/g. 
**Nephrotic range macroalbuminuria is defined as urine albumin:creatinine ratio >3000 mg/g.  





Table S2. Baseline Use and New Initiation of Concomitant Antihyperglycemic Therapy (On Treatment) 
 Baseline use New Initiation 
Participants, n (%) 
Canagliflozin 
(n = 2200) 
Placebo 
(n = 2197) 
Total 
 (N = 4397) 
Canagliflozin 
(n = 2200) 
Placebo 
(n = 2197) 
Total 
 (N = 4397) 
Alpha glucosidase inhibitors 66 (3.0) 73 (3.3) 139 (3.2) 10 (0.5) 16 (0.7) 26 (0.6) 
Biguanides  1275 (58.0) 1268 (57.7) 2543 (57.8) 55 (2.5) 80 (3.6) 135 (3.1) 
DPP-4 inhibitors 378 (17.2) 373 (17.0) 751 (17.1) 92 (4.2) 105 (4.8) 197 (4.5) 
GLP-1 receptor agonists 89 (4.0) 94 (4.3) 183 (4.2) 54 (2.5) 57 (2.6) 111 (2.5) 
Insulin 1451 (66.0) 1431 (65.1) 2882 (65.5) 98 (4.5) 132 (6.0) 230 (5.2) 
Sulfonylurea 611 (27.8) 656 (29.9) 1267 (28.8) 61 (2.8) 95 (4.3) 156 (3.5) 




Table S3. Reasons for Premature Discontinuation of Randomized Treatment 
Participants, n (%) 
Canagliflozin 
(n = 2200) 
Placebo 
(n = 2197) 
Any reason 543 (24.7) 658 (29.9) 
     Adverse event* 263 (12.0) 285 (13.0) 
     Personal reasons 164 (7.5) 199 (9.1) 
     Poor compliance 16 (0.7) 18 (0.8) 
     Safety or tolerability 13 (0.6) 19 (0.9) 
     Dialysis or renal transplant 18 (0.8) 28 (1.3) 
     Disallowed therapy 2 (0.1) 17 (0.8) 
     Protocol violation 3 (0.1) 3 (0.1) 
     Site closure 3 (0.1) 3 (0.1) 
     Other 61 (2.8) 86 (3.9) 






Table S4. Summary of Safety Results* 
 n/N 
Event rate per  
1000 patient-years  
 Canagliflozin Placebo Canagliflozin Placebo Hazard ratio (95% CI)† 
All adverse events 1784/2200 1860/2197 351.4 379.3 0.87 (0.82–0.93) 
All serious adverse events 737/2200 806/2197 145.2 164.4 0.87 (0.79–0.97) 
Serious adverse events related to study drug 62/2200 42/2197 12.2 8.6 1.45 (0.98–2.14) 
Amputation 70/2200 63/2197 12.3 11.2 1.11 (0.79–1.56) 
Fracture‡ 67/2200 68/2197 11.8 12.1 0.98 (0.70–1.37) 
Cancer      
Renal cell carcinoma‡ 1/2200 5/2197 0.2 0.9 –† 
Breast§ 8/761 3/731 4.1 1.6  2.59 (0.69–9.76) 
Bladder 10/2200 9/2197 1.7 1.6  1.10 (0.45–2.72) 




Hyperkalemia¶ 151/2200 181/2197 29.7 36.9 0.80 (0.65–1.00) 
Acute kidney injury 86/2200 98/2197 16.9 20.0 0.85 (0.64–1.13) 
Diabetic ketoacidosis‡, # 11/2200 1/2197 2.2 0.2 10.80 (1.39–83.65) 
Osmotic diuresis 51/2200 40/2197 10.0 8.2  1.25 (0.83–1.89) 
Volume depletion 144/2200 115/2197 28.4 23.5  1.25 (0.97–1.59) 
Hypoglycemia 225/2200 240/2197 44.3 48.9  0.92 (0.77–1.11) 
Urinary tract infection 245/2200 221/2197 48.3 45.1 1.08 (0.90–1.29) 
Genital mycotic infection      
Male 28/1439 3/1466 8.4 0.9 9.30 (2.83–30.60) 
Female 22/761 10/731 12.6 6.1 2.10 (1.00–4.45) 
Hypersensitivity/cutaneous reactions 23/2200 30/2197 4.5 6.1 0.75 (0.44–1.30) 
Hepatic injury 28/2200 32/2197 5.5 6.5 0.86 (0.52–1.43) 




Photosensitivity 1/2200 1/2197 0.2 0.2 –† 
Venous thromboembolism 21/2200 16/2197 4.1 3.3 1.28 (0.67–2.45) 
CI, confidence interval. 
*The numbers for amputation and fracture were based on the on-study analysis set, while the other safety endpoints were based on the on-
treatment analysis set.  
†Hazard ratios and 95% CIs were calculated for outcomes with >10 events. 
‡The analyses for fracture, renal cell carcinoma, acute pancreatitis, and diabetic ketoacidosis and were based on confirmed and adjudicated results.  
§Includes female participants only. 
¶Adverse events of hyperkalemia were spontaneously reported by the investigator. The summary counts provided for the adverse event of 
hyperkalemia include the MedDRA preferred terms of “hyperkalemia” and “blood potassium increased.” 
#All potential ketone-related events were adjudicated for diabetic ketoacidosis by an independent adjudication committee based on clinical 




Table S5. Summary of Adverse Events by Body System or Organ Class 
Body system or organ class, n (%) 
Canagliflozin  
(n = 2200) 
Placebo 
(n = 2197) 
All adverse events 1784 (81.1) 1860 (84.7) 
 Blood and lymphatic system disorders 120 (5.5) 200 (9.1) 
 Cardiac disorders 300 (13.6) 393 (17.9) 
 Congenital, familial and genetic disorders 9 (0.4) 6 (0.3) 
 Ear and labyrinth disorders 77 (3.5) 77 (3.5) 
 Endocrine disorders 57 (2.6) 55 (2.5) 
 Eye disorders 234 (10.6) 257 (11.7) 
 Gastrointestinal disorders 463 (21.0) 475 (21.6) 
 General disorders and administration site conditions 288 (13.1) 382 (17.4) 
 Hepatobiliary disorders 70 (3.2) 74 (3.4) 
 Immune system disorders 22 (1.0) 20 (0.9) 
 Infections and infestations 932 (42.4) 1016 (46.2) 
 Injury, poisoning and procedural complications 307 (14.0) 304 (13.8) 
 Investigations 343 (15.6) 451 (20.5) 
 Metabolism and nutrition disorders 604 (27.5) 690 (31.4) 




 Neoplasms benign, malignant and unspecified (including cysts and polyps) 132 (6.0) 122 (5.6) 
 Nervous system disorders 396 (18.0) 419 (19.1) 
 Pregnancy, puerperium and perinatal conditions 2 (0.1) 0 
 Product issues 2 (0.1) 4 (0.2) 
 Psychiatric disorders 93 (4.2) 112 (5.1) 
 Renal and urinary disorders 339 (15.4) 423 (19.3) 
 Reproductive system and breast disorders 101 (4.6) 92 (4.2) 
 Respiratory, thoracic and mediastinal disorders 263 (12.0) 310 (14.1) 
 Skin and subcutaneous tissue disorders 313 (14.2) 324 (14.7) 
 Social circumstances 1 (<0.1) 1 (<0.1) 
 Surgical and medical procedures 0 1 (<0.1) 





Table S6. Baseline Characteristics of Participants With Diabetic Ketoacidosis Adverse Events 
 
Participants with 
Diabetic Ketoacidosis*  
(n = 12) 
All Participants 
 (n = 4401) 
Background insulin treatment—no. (%) 11 (91.7) 2884 (65.5) 
Background metformin treatment—no. (%) 4 (33.3) 2545 (57.8) 
Duration of diabetes—yr 23.8 15.8 
Glycated hemoglobin—% 8.9 8.3 
Glycated hemoglobin >10%—no. (%)  3 (25.0) 450 (10.2) 
eGFR—mL/min/1.73 m2 54.0 56.2 
Screening eGFR 30 to <45 mL/min/1.73 m2—no. (%) 7 (58.3) 1313 (29.8) 
History of diabetic ketoacidosis 2 (16.7) 4 (0.1) 
*Precipitating factors (primarily recent or concurrent illness, recent reduction in insulin dose, or drugs 
affecting carbohydrate metabolism) were identified by the adjudication committee for 83% of cases (10 
of 12 events) in the canagliflozin group and 100% (1 event) in the placebo group. With the exception of 1 
case, concomitant blood glucose levels were >250 mg/dL (>13.9 mmol/L). 
 
